PRODUCT INFORMATION



sPLA₂ Inhibitor Item No. 17277

CAS Registry No.:	393569-31-8		
Formal Name:	γS-[(1-oxo-7-phenylheptyl)		
	amino]-4-(phenylmethoxy)-		H
	benzenepentanoic acid		Ń O
Synonyms:	KH064, Secretory Phospholipase		
	A ₂ Inhibitor		
MF:	$\bar{C_{31}H_{37}NO_4}$		
FW:	487.6		O OH
Purity:	≥95%		
Supplied as:	A crystalline solid		
Storage:	-20°C		
Stability:	≥4 years		
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.			

Laboratory Procedures

sPLA₂ inhibitor is supplied as a crystalline solid. A stock solution may be made by dissolving the sPLA₂ inhibitor in the solvent of choice, which should be purged with an inert gas. sPLA₂ inhibitor is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of sPLA2 inhibitor in ethanol and DMF is approximately 5 mg/ml and approximately 2 mg/ml in DMSO.

sPLA₂ inhibitor is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, sPLA₂ inhibitor should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. $sPLA_2$ inhibitor has a solubility of approximately 0.1 mg/ml in a 1:6 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Secreted phospholipases A_2 (sPLA₂s) are a diverse family of low molecular weight PLA₂s with tissue-specific expression patterns and actions.¹ The group IIA sPLA₂ (sPLA₂-IIA) was originally purified from platelets and exudates from patients with rheumatoid arthritis.¹ Its expression can be induced by inflammatory mediators, and mouse studies suggest that it may play roles in colorectal polyposis, atherosclerosis, and bacterial infections.^{1,2} sPLA₂ inhibitor is an orally active inhibitor of sPLA₂-IIA.³ It protects against intestinal reperfusion injury in rats when given at 10 mg/kg orally.³ sPLA₂ inhibitor also attenuates NF-κB signaling in lung cancer cells and protects against diet-induced metabolic syndrome in rats.^{4,5}

References

- 1. Murakami, M., Taketomi, Y., Miki, Y., et al. Recent progress in phospholipase A2 research: From cells to animals to humans. Prog. Lipid Res. 50(2), 152-192 (2011).
- 2. Murakami, M., Taketomi, Y., Girard, C., et al. Emerging roles of secreted phospholipase A₂ enzymes: Lessons from transgenic and knockout mice. Biochimie 92(6), 561-582 (2010).
- 3. Arumugam, T.V., Arnold, N., Proctor, L.M., et al. Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA₂, COX-1 and COX-2 selective inhibitors, and an LTC_4 receptor antagonist. Br. J. Pharmacol. 140(1), 71-80 (2003).
- Yu, J.A., Kalatardi, S., Dohse, J., et al. Group IIa sPLA2 inhibition attenuates NF-KB activity and promotes 4. apoptosis of lung cancer cells. Anticancer Res. 32(9), 3601-3607 (2012).
- 5. lyer, A., Lim, J., Poudyal, H., et al. An inhibitor of phospholipase A₂ group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats. Diabetes 61(9), 2320-2329 (2012).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/05/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM